The currently used clinical and pathological factors (such as histologic grade, hormone receptor status, human epidermal growth factor receptor 2 (HER2) status, tumor size, molecular subtype) are not sufficient to explain the diversity in treatment results [5]. Here, ERBB2 is linked to neoplasm.